ATS View
한국어

PharmGen Science KRX:004720KOSPI

팜젠사이언스 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h0
Articles, 7 days2
DART filings, 7 days0
Articles tracked29since Sep 11

In Q2 2026, PharmGen Science reported revenue of ₩47.7bn, up 4.0% year on year, and operating profit of ₩1.8bn. PharmGen Science (팜젠사이언스) appeared in 2 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 22 with 13 articles. The most common catalyst was clinical & approvals (2).

PharmGen Science quarterly results separate, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩47.7bn+4.0%₩1.8bn
margin 3.8%		−₩13.6bn
Q1 2026₩43.3bn+1.0%₩1.8bn
margin 4.1%		−₩988m
Q4 2025 derived₩42.8bn-3.2%−₩753m
margin −1.8%		−₩118bn
Q3 2025₩41.5bn-0.4%₩1.4bn
margin 3.3%		−₩2.3bn
Q2 2025₩45.9bn+6.9%₩3.3bn
margin 7.2%		₩3.9bn
Q1 2025₩42.9bn+0.9%₩2.0bn
margin 4.8%		−₩710m
Q4 2024 derived₩44.2bn-5.0%₩1.9bn
margin 4.2%		₩3.7bn
Q3 2024₩41.7bn+1.2%₩3.1bn
margin 7.3%		−₩3.9bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

PharmGen Science top stories 2 weeks, by number of outlets

  1. 1
    팜젠사이언스, 프란루카스트 건조시럽 첫 제네릭 허가
    4 outlets · 4 articlesFirst report Oct 22 09:20 메디파나뉴스
  2. 2
    팜젠사이언스, 소아용 프란루카스트 제네릭 허가…140억 시장 공략
    3 outlets · 3 articlesFirst report Oct 22 09:55 아시아경제
  3. 3
    팜젠사이언스, 소아용 천식치료제 제네릭 허가 획득
    1 outlets · 1 articlesFirst report Oct 22 09:28 FETVRegulatory approval
  4. 4
    팜젠사이언스, 프란루건조시럽 품목허가
    1 outlets · 1 articlesFirst report Oct 22 11:38 메디포뉴스Regulatory approval
  5. 5
    팜젠사이언스, 소아용 프란루카스트 제네릭 선점...내년 1월 출시 목표
    1 outlets · 1 articlesFirst report Oct 22 10:19 EBN
  6. 6
    팜젠사이언스, 지역 유해식물 제거 환경정화 활동 진행
    1 outlets · 1 articlesFirst report Oct 19 10:37 더바이오

Latest PharmGen Science news Korean headlines